Related Experiment Video
Updated: May 23, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Visfatin levels in nonalcoholic fatty liver disease
Erdem Akbal1, Erdem Koçak, Adnan Taş
1Department of Gastroenterology, Ankara Education and Research Hospital, Ankara, Turkey. drerdemakbal@gmail.com
Purpose:
Recently, role of adipokin in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) has been suggested. Among adipokins, role of leptin and adiponectin is rather well known; however, there are only a few data concerning visfatin.
Material And Methods:
NAFLD is confirmed in 30 patients by ultrasonography. As a control group, patients without fatty liver or other liver diseases were included. Viral hepatitis, metabolic liver diseases, and autoimmune hepatitis and consumption of alcohol were excluded in all patients. Fasting serum level of visfatin was determined by ELISA method.
Results:
Serum visfatin concentration in the NAFLD group (14.7 ± 8.1 ng/ml) was significantly higher than in controls (9.4 ± 1.6 ng/ml) (P < 0.001). There were no correlations between visfatin and anthropometric parameters, transaminases, lipids, and homeostasis model assessment-estimated insulin resistance (HOMA-IR).
Conclusion:
Serum visfatin concentration increases in patients with NAFLD.
Related Concept Videos
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Cirrhosis I: Introduction
Cirrhosis II: Pathophysiology

